(A) Time spent in closed arm, (B) Time spent in open arm, (C) Number of entries in closed arm, (D) Number of entries in open arm, and (E) Latency time to enter open arm for elevate... by Hammad Ismail (4227988)

(A) Time spent in light compartment, (B) Number of transitions between compartments, (C) Number of head pokes to light compartment for light-dark compartment test. by Hammad Ismail (4227988)

(A) Number of crossings, (B) Number of rearings, (C) Latency time for novel object, (D) Familiar object exploration time, (E) Novel object exploration time for novel object recogni... by Hammad Ismail (4227988)

(A) Mobility rate, (B) Explored areas, (5C) Immobility time, (D) Frozen events for hole board test. by Hammad Ismail (4227988)

(A) Immobility time, (B) Frozen events for forced swim test. by Hammad Ismail (4227988)

(A) Duration of contacts, (B) Distance covered, (C) Number of interacting contacts, (D) Number of frozen events for social interaction test. by Hammad Ismail (4227988)

The phosphorylation of Mas receptor and its induced-effects in <i>hGRK4</i> <i>γ</i> WT and 142V transgenic mice. by Lin Chen (54305)

A, Uncropped image of gel in Fig 1B. by Tomokazu Yamaguchi (8284989)

Subjects:

Cnot4 haploinsufficiency impairs rosiglitazone-induced transcriptional activity of PPAR by Tomokazu Yamaguchi (8284989)

Subjects:

Cnot4 mediates differentiation into adipocytes from mouse embryonic fibroblasts. by Tomokazu Yamaguchi (8284989)

Subjects:

Cnot4 heterozygosity confers resistance to high fat diet-induced obesity. by Tomokazu Yamaguchi (8284989)

Subjects:

Cnot4 homozygous knockout mice are embryonic lethal. by Tomokazu Yamaguchi (8284989)

Subjects:

Metabolic incorporation of ¹⁴C-acetate into PE and CL in cellular lipids of log-phase <i>M</i>. <i>abscessus</i> is affected by NMP. by Timilehin Faboro (20175963)

Efflux pump inhibitors NMP and PLU inhibit the viability of <i>Mycobacterium abscessus</i> biofilms. by Timilehin Faboro (20175963)

NMP and PLU inhibit efflux activity in <i>Mycobacterium abscessus</i>. by Timilehin Faboro (20175963)

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Mas Receptor Phosphorylation and its-mediated Effects in Renal Cortex of WKY Rats and SHRs. by Lin Chen (54305)

Renal GRK4 knockdown impacted Mas receptor phosphorylation and Its-induced renal function in SHRs. by Lin Chen (54305)